ArticleArtificial organs2026
Feasibility Testing of the 2nd Generation Inspired Therapeutics NeoMate System for Paracorporeal Support of Neonates and Infants in Heart Failure.
Article in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundInspired Therapeutics is advancing the development of the next generation of the NeoMate mechanical circulatory support (MCS) system for neonate and infant heart failure (HF) populations. The NeoMate system includes a low-cost magnetically-actuated paracorporeal centrifugal pump with an integrated, reusable motor and controller. This design iteration features a compact size (37 mm diameter), small prime volume (10 mL), and redesigned rotor and flow path. We present experimental data from computational fluid dynamics (CFD), mock loops, and acute animals.
methodsCFD models were used to improve pump design (wall shear stress, hemolysis index) and motor performance (torque, power, efficiency). Static mock loops (3.5 cP) were performed to evaluate hydrodynamics over a range of loads (0-300 mmHg) at 500-5500 rpm (n = 2 pumps tested, 24Fr inflow and 16Fr outflow cannula). A dynamic mock loop (3.5 cP) was tuned to HF, with the pump integrated LV apex-to-aorta and data collected from 0 to 5500 rpm. Two acute sheep studies were performed with each pump implanted paracorporeally: one LV apex-to-aorta (24Fr inflow, 16Fr outflow) and the other via the jugular vein (28Fr dual-lumen cannula).
resultsCFD pump and motor performance and hemolysis index metrics were achieved exceeding design criteria (2.5 L/min, 150 mmHg) in static (2.5 L/min flow, 250 mmHg pressure), dynamic (2.8 L/min flow), and animals (3.1 L/min flow, 60 mmHg aortic pressure, plasma free hemoglobin < 20 mg/dL) at 5500 rpm.
conclusionsThe next generation NeoMate pumps demonstrated favorable hydrodynamic, hemodynamic, and blood trauma performance, showing promising progress toward this technology to serve as a versatile therapy for neonates and infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.